Stanford University's 5th Annual Neuromuscular Conference: Spinal Muscular Atrophy & Duchenne Muscular Dystrophy - Lessons Learned in Genetic Treatments (Recorded Sessions)

Friday, February 2, 2024, 7:00 AM - Monday, February 1, 2027, 7:00 AM, On Demand

Internet Enduring Material Sponsored by Stanford University School of Medicine. Presented by the Division of Neuromuscular Medicine at Stanford University School of Medicine. 

New advances in genetic treatments require continuing medical education for all clinicians caring for individuals with neuromuscular disorders to assure that all eligible patients receive treatments quickly, and to optimize outcomes. Genetic treatments, supplemental treatments, regenerative approaches, and progress toward fetal therapy make this an exciting moment to discuss clinical-decision making.  Our goal is to improve use of these powerful new treatments and optimize patient management by including physicians, therapists, nurses, and all providers whether or not they see patients as part of specialized neuromuscular centers. 

This activity has the following goals: (1) review and understand new treatment developments over the past year; (2) examine novel insights and clinical reasoning that combine treatments and integrate rehabilitative management; and (3) use specific features of SMA & DMD to model optimal care, helping all providers understand evidence-based medical and rehabilitation approaches, whether or not they are members of specialized Neuromuscular care teams.

The activity will include an educational lecture series providing an overview of the new advances in SMA & DMD disease modifying therapies including gene correction and other course-modifying treatments, approaches to augment function that can be combined with genetic treatments, and developing regenerative and fetal treatments. Complex topics including, disability rights, fatigue and managing orthopedic conditions will be discussed.  At the end of this activity, participants will understand the use of genetic treatments, supplementary functional improvements, and other medical and rehabilitative approaches for SMA & DMD that provide models for optimizing neuromuscular care. Attendees will recognize opportunities to optimize clinical interventions and outcomes.

Release Date: February 2, 2024
Expiration Date: February 2, 2027
Estimated Time to Complete: ~11 hours
Registration Fee: FREE 
*Originally recorded on 12/8/2023 - 12/9/2023.

AMA PRA Category 1 Credits™ (14.50 hours), ANCC Contact Hours (14.50 hours), Non-Physician Participation Credit (14.50 hours)

1. Identify new advances in genetic and non-genetic treatments for SMA & DMD as well as anticipated developments that will further impact disease trajectories and outcomes.
2. Distinguish the unique disease factors influencing both fatigue and orthopedic health in individuals with SMA & DMD.
3. Utilize medical and rehabilitative interventions determined by evidence-based recommendations and established standards of care for best outcomes.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 14.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Nurses Credentialing Center (ANCC) 
Stanford Medicine designates this Live Activity for a maximum of 14.50 ANCC contact hours.  

Stanford Health Care Department of Rehabilitation is an approved provider for physical therapy, occupational therapy, and speech language pathology for courses that meet the requirements set forth by the respective California Boards. This course is approved for 14.50 hours CEU for PT, OT, and SLP.

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

Bibliography
View the Course Bibliography HERE

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

This CME Activity is supported in part by educational grants from Dyne Therapeutics, Inc., Genentech, Inc., Muscular Dystrophy Association, Parent Project Muscular Dystrophy, Inc., and Scholar Rock Inc.

Special Thank You to our Sponsors!
Avidity Biosciences, CureDuchenne & Catalyst Pharmaceuticals!